Taizhou Maibote Pharmaceutical

Taizhou Mabtech Pharmaceutical is a leading Chinese biopharmaceutical company focused on the development and large-scale manufacturing of monoclonal antibodies. As the primary operating subsidiary of the Hong Kong-listed Mabpharm Limited, the company operates a state-of-the-art production base in the China Medical City (Taizhou). Their portfolio features several approved biosimilars and biobetters, including CMAB007 (omalizumab) for asthma and CMAB008 (infliximab) for autoimmune disorders. The company integrates advanced R&D with high-capacity GMP manufacturing to provide cost-effective biologic therapies for oncology and immunological diseases. Mabtech is recognized for its proprietary expression systems and large-scale bioreactor technology.